These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 15997877)

  • 21. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of combined determinations of Epstein-Barr virus antibodies for nasopharyngeal carcinoma assessed with receiver operating characteristic curve based on logistic regression].
    Cai YL; Zheng YM; Cheng JR; Li J; Mo YK; Zhong QY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Oct; 23(5):384-7. PubMed ID: 20387494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
    Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the prognostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma.
    Twu CW; Wang WY; Liang WM; Jan JS; Jiang RS; Chao J; Jin YT; Lin JC
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):130-7. PubMed ID: 16979842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA.
    Yao JJ; Lin L; Jin YN; Wang SY; Zhang WJ; Zhang F; Zhou GQ; Cheng ZB; Qi ZY; Sun Y
    Cancer Sci; 2017 Aug; 108(8):1640-1647. PubMed ID: 28603915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
    Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
    Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus glycoprotein gH/gL antibodies complement IgA-viral capsid antigen for diagnosis of nasopharyngeal carcinoma.
    Li RC; Du Y; Zeng QY; Tang LQ; Zhang H; Li Y; Liu WL; Zhong Q; Zeng MS; Huang XM
    Oncotarget; 2016 Mar; 7(13):16372-83. PubMed ID: 27093005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology.
    Gu AD; Xie YB; Mo HY; Jia WH; Li MY; Li M; Chen LZ; Feng QS; Liu Q; Qian CN; Zeng YX
    J Gen Virol; 2008 May; 89(Pt 5):1152-1158. PubMed ID: 18420792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up.
    Shimakage M; Dezawa T; Chatani M
    Acta Otolaryngol; 2000 Jan; 120(1):100-4. PubMed ID: 10779195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
    Faggioni A; Corradini C; Venanzoni M; Cardi G; Bevere F; Barile G; Zompetta C; Frati L
    J Exp Pathol; 1987; 3(4):471-7. PubMed ID: 2842480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
    Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH; Pearson GR; Armstrong M; Bengali Z; Berenberg J; Easton J; Goepfert H; Henle G; Henle W; Heffner D; Huang A; Hyams VJ; Lanier A; Neel HB; Pilch B; Pointek N; Taylor W; Terebelo H; Weiland L
    Cancer Detect Prev; 1981; 4(1-4):307-12. PubMed ID: 6299561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of IgA specific antibodies to Epstein-Barr virus capsid and early antigens in nasopharyngeal carcinoma.
    Puthavathana P; Kositanont U; Chongkolwatana C; Metheetrairut C; Chantarakul N; Nuntarakchaikul S; Wasi C
    Asian Pac J Allergy Immunol; 1993 Jun; 11(1):39-43. PubMed ID: 8216557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic value of the Epstein-Barr virus serological markers in patients with nasopharyngeal carcinoma in cases of undetectable primary tumor location.
    Gurtsevitch VE; Senyuta NB; Lomaya MV; Ignatova AV; Dushenkina TE; Repkina IA; Pavlovskaya AI; Mudunov AM
    Vopr Virusol; 2016; 61(5):205-12. PubMed ID: 29323852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-IgA as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.
    Peng YH; Xu YW; Huang LS; Zhai TT; Dai LH; Qiu SQ; Yang YS; Chen WZ; Zhang LQ; Li EM; Xu LY
    Cancer Prev Res (Phila); 2015 Aug; 8(8):729-36. PubMed ID: 25990085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.